sosyomat.com

paxil hakkında

~24 ahkam var. 1 2 önceki sayfa »

bir yıl kullandım bir yığında kilo aldm.ha bunun yanında iyi şeylerde olmadı mı??oldu tabiki..ama geçiciymiş hepsi.yani bıraktım tüm o mutluluklar falan uçtu gitti..şimdi efexor die bişi içiorm o da aynı bırakınca gidicek biliyorum...

nymphamge   05 Ağustos 2008 20:24        (0 puan)  |    
rapor et



seviiiorummmm uleynnnn..

metabolizmaa   20 Haziran 2008 14:13        (0 puan)  |    
rapor et



bazılarına kilo verdirirken,bazılarınada aldırıyor..ama öle böle değil...aşırı yani..:D

heidiclumme   25 Nisan 2008 11:36        (0 puan)  |    
rapor et



hehehe..arkadaşın biri 'paxil, geçmişe daksil ' demiş..bayağı bi güldüm :D evet tamamen böyle...ruhunuzu paxilleyin,geçmişi daksilleyin..bir nevi deterjan reklamı gibi..:D 3 gündür dozunu azalttığım,ve ağzımın burnumun uyuştuğu,kulaklarımda kelebeklerin uçuştuğu bir etki sağlayan,ayrıca a-acayip derecede kendimi özüme döndüren mucizevi ilaç...evet bırakması zor,dünya tepetaklak oluyor ama,sıkıcas biras :D

heidiclumme   24 Nisan 2008 17:21        (0 puan)  |    
rapor et



daksil'in kız kardeşi

pinkcookie   20 Nisan 2008 22:03        (0 puan)  |    
rapor et



ne kadar deiştirdi bilemiorum ama tepkilerim çok yokoldu,sadece sinir,baırıp çaırmak diil,muhabbetlerde konuya katılmamı da engelledi uzun sürede ot etkisiymiş

pukole   20 Nisan 2008 21:50        (0 puan)  |    
rapor et



DRUG INTERACTIONS
Tryptophan: As with other serotonin reuptake inhibitors, an interaction between paroxetine and tryptophan may occur when they are coadministered. Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking immediate-release paroxetine. Consequently, concomitant use of PAXIL CR with tryptophan is not recommended (see WARNINGS—Serotonin Syndrome).

Monoamine Oxidase Inhibitors: See CONTRAINDICATIONS and WARNINGS.

Pimozide: In a controlled study of healthy volunteers, after immediate-release paroxetine hydrochloride was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and PAXIL CR is contraindicated (see CONTRAINDICATIONS).

Serotonergic Drugs: Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when PAXIL CR is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's Wort (see WARNINGS—Serotonin Syndrome). The concomitant use of PAXIL CR with other SSRIs, SNRIs or tryptophan is not recommended (see PRECAUTIONS—DRUG INTERACTIONS, Tryptophan).

Thioridazine: See CONTRAINDICATIONS and WARNINGS.

Warfarin: Preliminary data suggest that there may be a pharmacodynamic interaction (that causes an increased bleeding diathesis in the face of unaltered prothrombin time) between paroxetine and warfarin. Since there is little clinical experience, the concomitant administration of PAXIL CR and warfarin should be undertaken with caution (see Drugs That Interfere With Hemostasis).

Triptans: There have been rare postmarketing reports of serotonin syndrome with the use of an SSRI and a triptan. If concomitant use of PAXIL CR with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see WARNINGS—Serotonin Syndrome)

Drugs Affecting Hepatic Metabolism: The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug-metabolizing enzymes.

Cimetidine: Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a study where immediate-release paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week. Therefore, when these drugs are administered concurrently, dosage adjustment of PAXIL CR after the starting dose should be guided by clinical effect. The effect of paroxetine on cimetidine's pharmacokinetics was not studied.

Phenobarbital: Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30-mg dose of immediate-release paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment with PAXIL CR is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.

Phenytoin: When a single oral 30-mg dose of immediate-release paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T½ were reduced (by an average of 50% and 35%, respectively) compared to immediate-release paroxetine administered alone. In a separate study, when a single oral 300-mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when PAXIL CR is coadministered with phenytoin; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS—Postmarketing Reports).

Drugs Metabolized by CYP2D6: Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs, and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (> 90%), this CYP2D6 isozyme is saturated early during paroxetine dosing. In 1 study, daily dosing of immediate-release paroxetine (20 mg once daily) under steady-state conditions increased single-dose desipramine (100 mg) Cmax, AUC, and T½ by an average of approximately 2-, 5-, and 3-fold, respectively. Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold. The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when given with paroxetine.

Concomitant use of PAXIL CR with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either PAXIL CR or the other drug.

Therefore, coadministration of PAXIL CR with other drugs that are metabolized by this isozyme, including certain drugs effective in the treatment of major depressive disorder (e.g., nortriptyline, amitriptyline, imipramine, desipramine, and fluoxetine), phenothiazines, risperidone, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.

However, due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered (see CONTRAINDICATIONS and WARNINGS).

At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450 isozymes that, unlike CYP2D6, show no evidence of saturation (see PRECAUTIONS—Tricyclic Antidepressants).

Drugs Metabolized by Cytochrome CYP3A4: An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics. In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine. Based on the assumption that the relationship between paroxetine's in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine's extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.

Tricyclic Antidepressants (TCAs): Caution is indicated in the coadministration of TCAs with PAXIL CR, because paroxetine may inhibit TCA metabolism. Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is coadministered with PAXIL CR (see PRECAUTIONS—Drugs Metabolized by Cytochrome CYP2D6).

Drugs Highly Bound to Plasma Protein: Because paroxetine is highly bound to plasma protein, administration of PAXIL CR to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse events. Conversely, adverse effects could result from displacement of paroxetine by other highly bound drugs.

Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.): Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin potentiated the risk of bleeding. Thus, patients should be cautioned about the use of such drugs concurrently with paroxetine.

Alcohol: Although paroxetine does not increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking PAXIL CR.

Lithium: A multiple-dose study with immediate-release paroxetine hydrochloride has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when immediate-release paroxetine hydrochloride is coadministered with lithium.

Digoxin: The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state. Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine. Since there is little clinical experience, the concurrent administration of PAXIL CR and digoxin should be undertaken with caution.

Diazepam: Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.

Procyclidine: Daily oral dosing of immediate-release paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.

Beta-Blockers: In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with immediate-release paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated (see ADVERSE REACTIONS— Postmarketing Reports).

Theophylline: Reports of elevated theophylline levels associated with immediate-release paroxetine treatment have been reported. While this interaction has not been formally studied, it is recommended that theophylline levels be monitored when these drugs are concurrently administered.

Fosamprenavir/Ritonavir: Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).

Electroconvulsive Therapy(ECT): There are no clinical studies of the combined use of ECT and PAXIL CR.

metabolizmaa   17 Nisan 2008 22:13        (0 puan)  |    
rapor et



paroksetin..

metabolizmaa   17 Nisan 2008 22:06        (0 puan)  |    
rapor et



bende kullandim hiç bişii degişmedi hayatımda doktorcugumda efexor die bişeye geçti kimi iyi diyo kimi kötü diyo korkuyorum yaw bundan daha manyak olabilirmiyim ki ...

panic angelic   19 Mart 2008 16:56        (0 puan)  |    
rapor et



mutluluk haplarım benim :)

sam orpheus   15 Şubat 2008 08:48        (0 puan)  |    
rapor et



Hayatımı kurtardı...Yaklaşık iki yıldır kullanıyorum ve kendim olmama yardım etti...Meğer ne çok defom varmış da ben görmüyormuşum...Beynimin bana oynadığı oyunlarla stratejik yöntemler geliştirip savaştan galip çıkmamı sağladı...Nasıl mı?Bir süre sistemlerimi uyutarak dinlendirdi...Kendimi dinlememi sağladı...Şimdi iyiyim...Anlaşmamız bu kadardı bir kaç ay içerisinde bırakıyorum onu...Birdaha görüşmemek üzere...Artık kendi stratejilerim var çünkü:)...NVRTS ailesine sevgiler...

Erinye   31 Ocak 2008 22:48        (0 puan)  |    
rapor et



psi.prof.dr u kontrolunde 16 gündür yerine efexor koyup bırakmaya uğraştığım şerefsiz antidepresan.panik atağın 1.seçim ilacı olduğu kesindir eşşek gibi bezginlik yapar,4 sayfalık a4 büyüklüğünde prospektüsü ve bırakırken çektirdiği panik ataklar wardır.anafranil kullanın daha iyi.12 senedir antidepresan kullanıyorum 3 senedir de paxil kullanıyorum bırakılması bu kadar zor olan başka bir ilaç daha warsa o da kesin yeşil reçeteli bişeydir...

sadcore   11 Ocak 2008 20:11        (0 puan)  |    
rapor et



rakıyla birlikte manyak kafa yapar. tecrübeyle sabit.

RenkliGolge   04 Ekim 2007 01:30        (0 puan)  |    
rapor et



paxil, geçmişe daksil !!

Defconone   10 Haziran 2007 16:39        (2 puan)  |    
rapor et



bi halta yaramıyor o,ya da bende beklenen etkiyi vermedi

dubara   03 Haziran 2007 00:44        (0 puan)  |    
rapor et



kullanıyorum mutluyum.

Hell Raiser   29 Mart 2007 21:09        (0 puan)  |    
rapor et



paxil çakmak

Telemakus   26 Mart 2007 10:02        (0 puan)  |    
rapor et



ilacı almayı unuttugunuzda beyinde elektroşok dalgaları yaratan,her daimm hop hop oturtup kaldıran fenalık geçirtecek bir ruh haliiylee, dilinizi damagınızı kurutarak damacanayı agza dayayıp su icirtecek nitelikdeki anlamsız bir ilacdır. ne ise yaradıgını cozemedim henuz. bagımlılık yapar mı bilemiorum ama bu ilac yuzunden deri kemik butunleşmesi yasadıgımı gorebilio herkezz..!!!

rigigirl   25 Ocak 2007 20:30        (0 puan)  |    
rapor et



ilacı kullananların prospektüsü okumamasını tavsiye ederim.akabinde panik atak geçirebilirsiniz.şimdi böyle deyince de kesin gidip okursunuz:)

peyote   09 Aralık 2006 13:30        (0 puan)  |    
rapor et



bana vermedi kimse. iyi mi o kdr yani?

julianne   27 Ekim 2006 17:35        (0 puan)  |    
rapor et